Glycospingolipids (GSLs) have been implicated as fusion co-factors for human immunodeficiency virus (HIV) the causative agent of AIDS. The overall goal of the proposed research is to determine the role(s) of GSLs in the interaction of HIV-1-associated gp120 with different cell types of the central nervous system (CNS) or models thereof, and to use that information to develop possible inhibitors of that interaction. Emphasis is placed on CNS cells or possible models thereof because many individuals infected with HIV-1 eventually develop HIV-1-associated dementia (HAD) in the absence of opportunistic infection.
The specific aims of this proposal are to: 1) identify which GSL(s) is/are the ligand(s) for HIV-1-associated gp120. Experiments will be done to confirm that GSLs are necessary for HIV-1 entry and, in those instances where they are necessary, the GSLs adhered to by HIV-1 will be identified. 2) determine the contribution of the GSL saccharide and ceramide moieties to interactions with HIV-1-associated gp120. Experiments will be carried out to determine whether the saccharide portion of each GSL adhered to by HIV-1 can inhibit HIV-1 adherence to the GSL immobilized on plastic or whether a """"""""multivalent"""""""" saccharide or the ceramide portion per se is needed. 3) determine whether the inhibitor of HIV-1 associated gp120-mediated adherence to a GSL is able to inhibit gp120-mediated entry of the virus into cells expressing the GSL. The effectiveness of the inhibitor identified in the 2nd aim at blocking infection will be monitored using microglia and asrtrocytes. The effectiveness of the virus at inducing apoptosis in neuroblastoma cells in the presence and absence of inhibitor will also be ascertained. The results should indicate the portion of the GSL(s) recognized by HIV-1. They may also provide the basis for development of an inhibitor able to block adherence of HIV-1 to its GSL fusion co-factor thereby blocking its entry into the cell.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR-5 (01))
Program Officer
Kerza-Kwiatecki, a P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Pennsylvania State University
Schools of Medicine
United States
Zip Code
Rosa Borges, Andrew; Wieczorek, Lindsay; Johnson, Benitra et al. (2010) Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology 408:80-8
Schengrund, Cara-Lynne (2006) Glycoconjugates: roles in neural diseases caused by exogenous pathogens. CNS Neurol Disord Drug Targets 5:381-9
Crino, Peter B (2005) Molecular pathogenesis of focal cortical dysplasia and hemimegalencephaly. J Child Neurol 20:330-6
Rosa Borges, A; Schengrund, C-L (2005) Dendrimers and antivirals: a review. Curr Drug Targets Infect Disord 5:247-54
Kensinger, Richard D; Yowler, Brian C; Benesi, Alan J et al. (2004) Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. Bioconjug Chem 15:349-58
Kensinger, Richard D; Catalone, Bradley J; Krebs, Fred C et al. (2004) Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 48:1614-23
Baybis, Marianna; Lynch, David; Lee, Allana et al. (2004) Altered expression of neurotransmitter-receptor subunit and uptake site mRNAs in hemimegalencephaly. Epilepsia 45:1517-24
Baybis, Marianna; Yu, Jia; Lee, Allana et al. (2004) mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol 56:478-87
Schengrund, Cara-Lynne (2003) ""Multivalent"" saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem Pharmacol 65:699-707